Oral Anti-Diabetic Drugs Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Market Size (2027) | USD 52.92 Billion |
| Market Size (2032) | USD 64.93 Billion |
| Growth Rate (2027 - 2032) | 4.17 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Oral Anti-Diabetic Drugs Market Analysis by Mordor Intelligence
The Oral Anti-Diabetic Drugs Market size is projected to expand from USD 50.80 billion in 2026 and USD 52.92 billion in 2027 to USD 64.93 billion by 2032, registering a CAGR of 4.17% between 2027 and 2032.
The COVID-19 pandemic has had a substantial impact on the oral anti-diabetic drugs market. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with SARS-CoV-2 have underlined the importance of the oral anti-diabetic drugs market. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the oral anti-diabetic drugs market's growth globally.
The oral anti-diabetic drugs market has undergone significant transformation due to the increasing availability of generic therapies across major treatment classes. Patent expirations of several established diabetes medicines have intensified market competition, improved affordability, and expanded patient access to long-term treatment. The growing penetration of generic products, particularly in emerging economies, continues to support prescription volumes and broader utilization of oral anti-diabetic therapies.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Global Oral Anti-Diabetic Drugs Market Trends and Insights
Biguanide Segment Occupies the Highest Market Share in the Oral Anti-Diabetic Drugs Market in the current year
Biguanide Segment holds the highest share of about 45% in the Oral Anti-Diabetic Drugs Market in the current year.
Metformin is classified as a biguanide used for treating type 2 diabetes. It is prescribed for its off-label use in people with conditions such as insulin resistance. Since the introduction of metformin in T2DM therapy, many patients were treated successfully with this globally available medication. It includes a favorable risk/benefit profile recommended by IDF guidelines as a first-line drug. Long-term positive experience with the use of metformin, strong evidence of clinical efficacy, safety, high adherence rate, low cost, general availability, and cost-effectiveness are the contributing factors to the high market share. The World Health Organization put metformin on the list of essential medicines: 'medicines that satisfy the priority of health care needs of the population.'
Oral anti-diabetic drugs comprise several therapeutic classes, including biguanides, sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, meglitinides, and alpha-glucosidase inhibitors. The availability of multiple treatment options allows healthcare providers to tailor therapy according to patient characteristics, disease severity, cardiovascular risk, and comorbidity profiles. In recent years, the growing preference for therapies offering additional cardiovascular and renal benefits has influenced prescribing patterns, driving continuous evolution within the oral anti-diabetic drugs market.
Market participants are increasingly focusing on product innovation, combination therapies, and regulatory approvals to strengthen their presence in the oral anti-diabetic drugs market. For instance, in June 2024, Farxiga (dapagliflozin) received an expanded FDA approval for use in pediatric patients aged 10 years and older with type 2 diabetes, highlighting the ongoing expansion of indications for oral anti-diabetic therapies and the industry's focus on addressing unmet patient needs across different age groups.
Owing to the factors above and the increasing prevalence, the market will likely continue to grow.
Asia-Pacific Region is Expected to witness highest CAGR in the Oral Anti-Diabetic Drugs Market over the forecast period
The Asia-Pacific region is expected to register a CAGR of more than 5% over the forecast period.
According to International Diabetes Federation, 90 million adults lived with diabetes in the IDF South-East Asia Region and 206 million adults in the IDF Western Pacific Region in 2021. This figure is estimated to increase to 113 million and 238 million by 2030. The use of oral anti-diabetes drugs is rising because new-generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
China and Japan are recognized as potential developing markets in the Asia-Pacific region due to the growing diabetic population. Japan is a mature market with associated challenges, like slow economic growth, an aging population, and increased competition. The country is witnessing a significant increase in generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
Diabetes reduces lifespan, and people with the disease are likely to experience blindness and be hospitalized for amputations, kidney failure, heart attacks, strokes, and heart failure. First-line therapy used in patients with T2D is metformin monotherapy. Other options must be considered when metformin is contraindicated or not tolerated or when treatment goals are not achieved after three months of use at the maximum tolerated dose. The growing spectrum of diabetes mellitus drugs includes dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists, generally used to supplement treatment with metformin.
The market is expected to grow during the forecast period due to the factors above.
Competitive Landscape
The oral anti-diabetes drug market is moderately fragmented, with major manufacturers like Eli Lilly, AstraZeneca, Sanofi, Janssen Pharmaceuticals, etc., having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets.
Oral Anti-Diabetic Drugs Industry Leaders
-
Eli Lilly and Company
-
Astellas Pharma Inc.
-
Sanofi S.A.
-
Janssen Pharmaceuticals
-
AstraZeneca
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- July 2022: Glenmark Pharmaceuticals Limited announced that it had launched sitagliptin and its Fixed Dose Combinations (FDCs) for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price.
- March 2022: Oramed announced ORMD-0801 (a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
Global Oral Anti-Diabetic Drugs Market Report Scope
Oral diabetes drugs help manage blood glucose levels in patients whose bodies still produce some insulin, such as those with type 2 diabetes. These medicines are prescribed along with regular exercise and changes in the diet. The Oral Anti-Diabetic Drugs Market is segmented into drugs (Biguanides (Metformin), Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists (Bromocriptin (Cycloset)), Sodium-glucose Cotransport-2 (SGLT-2) inhibitor (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin)), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin)), Sulfonylureas, and Meglitinides), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The report offers the value (in USD million) and volume (in units million) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
| Biguanides | Metformin |
| Alpha-glucosidase inhibitors | Alpha-glucosidase Inhibitors |
| Dopamine -D2 Receptor Agonist | Bromocriptin (Cycloset) |
| Sodium-glucose Cotransport -2 (SGLT-2) inhibitor | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Suglat (Ipragliflozin) | |
| Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors | Januvia (Sitagliptin) |
| Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina (Alogliptin) | |
| Galvus (Vildagliptin) | |
| Sulfonylureas | Sulfonylureas |
| Meglitinides | Meglitinides |
| North America | United States |
| Canada | |
| Rest of North America | |
| Europe | France |
| Germany | |
| Italy | |
| Spain | |
| United Kingdom | |
| Russia | |
| Rest of Europe | |
| Latin America | Mexico |
| Brazil | |
| Rest of Latin America | |
| Asia-Pacific | Japan |
| South Korea | |
| China | |
| India | |
| Australia | |
| Vietnam | |
| Malaysia | |
| Indonesia | |
| Philippines | |
| Thailand | |
| Rest of Asia-Pacific | |
| Middle East and Africa | Saudi Arabia |
| Iran | |
| Egypt | |
| Oman | |
| South Africa | |
| Rest of Middle East and Africa |
| Drugs | Biguanides | Metformin |
| Alpha-glucosidase inhibitors | Alpha-glucosidase Inhibitors | |
| Dopamine -D2 Receptor Agonist | Bromocriptin (Cycloset) | |
| Sodium-glucose Cotransport -2 (SGLT-2) inhibitor | Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors | Januvia (Sitagliptin) | |
| Onglyza (Saxagliptin) | ||
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina (Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Sulfonylureas | Sulfonylureas | |
| Meglitinides | Meglitinides | |
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Europe | France | |
| Germany | ||
| Italy | ||
| Spain | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Latin America | Mexico | |
| Brazil | ||
| Rest of Latin America | ||
| Asia-Pacific | Japan | |
| South Korea | ||
| China | ||
| India | ||
| Australia | ||
| Vietnam | ||
| Malaysia | ||
| Indonesia | ||
| Philippines | ||
| Thailand | ||
| Rest of Asia-Pacific | ||
| Middle East and Africa | Saudi Arabia | |
| Iran | ||
| Egypt | ||
| Oman | ||
| South Africa | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
How big is the Oral Anti-Diabetic Drugs Market?
The Oral Anti-Diabetic Drugs Market size is expected to reach USD 52.92 billion in 2027 and grow at a CAGR of 4.17% to reach USD 64.93 billion by 2032.
What is the current Oral Anti-Diabetic Drugs Market size?
In 2026, the Oral Anti-Diabetic Drugs Market size is expected to reach USD 50.80 billion.
Who are the key players in Oral Anti-Diabetic Drugs Market?
Eli Lilly and Company, Astellas Pharma Inc., Sanofi S.A., Janssen Pharmaceuticals and AstraZeneca are the major companies operating in the Oral Anti-Diabetic Drugs Market.
Which is the fastest growing region in Oral Anti-Diabetic Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2027-2032).
Which region has the biggest share in Oral Anti-Diabetic Drugs Market?
In 2026, the Asia-Pacific accounts for the largest market share in Oral Anti-Diabetic Drugs Market.
What years does this Oral Anti-Diabetic Drugs Market cover, and what was the market size in 2025?
In 2025, the Oral Anti-Diabetic Drugs Market size was estimated at USD 48.77 billion. The report covers the Oral Anti-Diabetic Drugs Market historical market size for years: 2021, 2022, 2023, 2024, 2025, and 2026. The report also forecasts the Oral Anti-Diabetic Drugs Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.